Thurston Springer Miller Herd & Titak Inc. Lowers Stock Holdings in Cencora, Inc. $COR

Thurston Springer Miller Herd & Titak Inc. lowered its position in Cencora, Inc. (NYSE:COR) by 93.6% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 602 shares of the company’s stock after selling 8,838 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Cencora were worth $188,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Cencora by 5.3% in the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after acquiring an additional 1,125,661 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Cencora by 8.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after purchasing an additional 787,858 shares in the last quarter. Geode Capital Management LLC boosted its stake in Cencora by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock worth $1,429,772,000 after purchasing an additional 284,229 shares during the period. Norges Bank purchased a new stake in Cencora during the 2nd quarter valued at approximately $695,215,000. Finally, Viking Global Investors LP raised its position in shares of Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the sale, the chief executive officer directly owned 65,746 shares in the company, valued at $24,105,113.44. This trade represents a 7.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 15,290 shares of company stock worth $5,012,227. Corporate insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of a number of research reports. Wells Fargo & Company upped their target price on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. JPMorgan Chase & Co. lifted their target price on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. UBS Group boosted their target price on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, TD Cowen raised their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $373.25.

Cencora Stock Down 2.5%

Shares of NYSE COR opened at $341.63 on Wednesday. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $377.54. The firm’s 50-day moving average price is $344.85 and its 200-day moving average price is $312.26. The stock has a market capitalization of $66.27 billion, a price-to-earnings ratio of 42.97, a P/E/G ratio of 1.66 and a beta of 0.63.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same period in the previous year, the firm posted $3.34 earnings per share. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is presently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.